Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD
Digital Health Global
APRIL 16, 2024
(Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has entered into a licensing agreement with Braingaze Ltd.
Let's personalize your content